BDBM439594 US10633345, Compound 224b::US10689346, Compound 224b::US11203574, Compound 224b::US11230530, Compound 224b::US11708332, Compound 224b

SMILES Nc1n[nH]c2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F

InChI Key InChIKey=NXXQRHGMCLMJHS-UHFFFAOYSA-N

Data  6 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 439594   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439594(US10689346, Compound 224b | US10633345, Compound 2...)
Affinity DataKi: >100nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439594(US10689346, Compound 224b | US10633345, Compound 2...)
Affinity DataKi: >100nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/17/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439594(US10689346, Compound 224b | US10633345, Compound 2...)
Affinity DataKi: >100nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439594(US10689346, Compound 224b | US10633345, Compound 2...)
Affinity DataKi: >100nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439594(US10689346, Compound 224b | US10633345, Compound 2...)
Affinity DataKi: >100nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439594(US10689346, Compound 224b | US10633345, Compound 2...)
Affinity DataKi: >100nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent